What is claimed is:

1. A humanised antibody comprising a heavy chain variable region comprising one, two or three of the following complementarity determining regions:

(i) CDRH1 as set out in SEQ ID NO:2

(ii) CDRH2 as set out in SEQ ID NO:3

(iii) CDRH3 as set out in SEQ ID NO:4, or a CDRH3 as set out in any of SEQ ID NO:132-137

wherein the antibody further comprises at least one of a lysine residue at position 66, a leucine residue at position 69, or a valine at position 71 of the heavy chain variable region (numbering according to Kabat).

2. The antibody of claim 1, wherein the antibody comprises a leucine residue at position 69 of the heavy chain variable region.

3. The antibody of claim 1 or 2, which comprises a heavy chain variable region comprising CDRH1 as set out in SEQ ID NO:2, CDRH2 as set out in SEQ ID NO:3 and CDRH3 as set out in SEQ ID NO:4.

4. The antibody of claim 1 or 2, which comprises a heavy chain variable region comprising CDRH1 as set out in SEQ ID NO:2, CDRH2 as set out in SEQ ID NO:3, and CDRH3 with a sequence selected from the group consisting of: SEQ ID NO:132, 133, 134, 135, 136 or 137.

5. The antibody of claim 1, which comprises a heavy chain variable region with a sequence selected from the group consisting of SEQ ID NO:10, 11, 12, 13, 14, 15, 16, 17, 121, 123, 125, 127, 129 or 131.

6. The antibody of claim 5, which comprises a heavy chain variable region of SEQ ID NO:13 (1A11.H3 V_H).

7. The antibody of any preceding claim, comprising a heavy chain of SEQ ID NO:114 or SEQ ID NO:118.

8. The antibody of claim 5, which comprises a heavy chain variable region of SEQ ID NO:121 or SEQ ID NO:123.

9. The antibody of any preceding claim, further comprising a light chain variable region comprising one, two or three of the following complementarity determining regions:

(iv) CDRL1 as set out in SEQ ID NO:5

(iv) CDRL2 as set out in SEQ ID NO:6

(v) CDRL3 as set out in SEQ ID NO:7.

10. The antibody of claim 9, wherein the light chain variable region further comprises at least one residue selected from the group consisting of: a lysine residue at position 45, a proline residue at position 46, a tryptophan residue at position 47, a valine residue at position 58, a valine residue at position 60, a serine residue at position 70, and a tyrosine residue at position 71 of the variable region light chain (numbering according to Kabat).

11. The antibody of any preceding claim, which comprises: a heavy chain variable domain comprising the following complementarity determining regions:

(i) CDRH1 as set out in SEQ ID NO:2

(ii) CDRH2 as set out in SEQ ID NO:3

(iii) CDRH3 as set out in SEQ ID NO:4, or a CDRH3 as set out in any of SEQ ID NO:132-137

and a light chain variable domain comprising the following complementarity determining regions:

(iv) CDRL1 as set out in SEQ ID NO:5

(v) CDRL2 as set out in SEQ ID NO:6

(vi) CDRL3 as set out in SEQ ID NO:7

wherein the antibody further comprises a leucine residue at position 69 of the heavy chain variable region, and a proline residue at position 46 of the light chain variable region.

12. The antibody of any preceding claim, comprising a light chain variable region of SEQ ID NO:22.

13. The antibody of any of claims 1 to 12, which comprises a light chain of SEQ ID NO:115.

14. The antibody of claim 1, wherein said antibody comprises a heavy chain variable region as set out in SEQ ID NO:13, and a light chain variable region as set out in SEQ ID NO:22.

15. An antigen binding protein comprising one or more of the following complementarity determining regions:

(i) CDRH1 as set out in SEQ ID NO:2 or a variant CDR thereof

(ii) CDRH2 as set out in SEQ ID NO:3 or a variant CDR thereof

(iii) CDRH3 as set out in SEQ ID NO:4 or a variant CDR thereof, or a CDRH3 as set out in any of SEQ ID NO:132-137

(iv) CDRL1 as set out in SEQ ID NO:5 or a variant CDR thereof

(v) CDRL2 as set out in SEQ ID NO:6 or a variant CDR thereof

(vi) CDRL3 as set out in SEQ ID NO:7 or a variant CDR thereof

wherein at least one of said CDRs is a variant CDR or wherein CDRH3 has a sequence as set out in SEQ ID NO:132-137, and wherein said antigen binding protein is capable of binding to CD127.

16. The antigen binding protein of claim 15, which comprises the following complementarity determining regions:

(i) CDRH1 as set out in SEQ ID NO:2

(ii) CDRH2 as set out in SEQ ID NO:3

(iii) CDRH3 as set out in any of SEQ ID NO:132-137

(iv) CDRL1 as set out in SEQ ID NO:5

(v) CDRL2 as set out in SEQ ID NO:6

(vi) CDRL3 as set out in SEQ ID NO:7.

17. The antigen binding protein of claim 15 or 16, which comprises a light chain variable region of SEQ ID NO:22.

18. The antigen binding protein of claim 15, 16 or 17, which comprises a heavy chain variable region of SEQ ID NO:13, with one or more substitutions in the heavy chain, said substitutions selected from the group consisting of: N98D, N98E, F100bE, F100bH, F100bI and F100bV.

19. The antigen binding protein according to claim 15, 16 or 17, which comprises a heavy chain variable region selected from the group consisting of SEQ ID NO:121, 123, 125, 127, 129 and 131.

20. An antigen binding protein, comprising a heavy chain variable region as set out in SEQ ID NO:13, and a light chain variable region as set out in SEQ ID NO:22.

21. An antigen binding protein according to claim 20, comprising a heavy chain as set out in SEQ ID NO:114 or SEQ ID NO:118 and a light chain as set out in SEQ ID NO:115.

22. A nucleic acid molecule encoding an antibody or antigen binding protein according to any of claims 1 to 20.

23. An expression vector comprising a nucleic acid molecule according to claim 22.

24. A recombinant host cell comprising an expression vector according to claim 23.

25. An antibody or antigen binding protein expressed by a host cell according to claim 24.

26. A method for the production of an antigen binding protein, comprising the step of culturing a host cell according to claim 24 in a medium to produce the antigen binding protein, and isolating or purifying the antigen binding protein therefrom.

27. A method according to claim 26, wherein said culturing step is performed in conditions conducive for expression of the antibody or antigen binding protein from the host cell, and secretion of the antibody from the cell.

28. A pharmaceutical composition comprising an antigen binding protein according to any of claims 1 to 20 and a pharmaceutically acceptable carrier or excipient.

29. Use of an antigen binding protein according to any of claims 1 to 20, in the manufacture of a medicament for treating a subject afflicted with an autoimmune or inflammatory disease.

30. The use according to claim 29, wherein the autoimmune or inflammatory disease is multiple sclerosis.

What is claimed is:

1. An isolated antigen-binding protein comprising a heavy chain variable region with a sequence selected from the group consisting of SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 121, 123, 125, 127, 129 and 131 and a light chain variable region comprising the following complementarity determining regions:

(i) CDRL1 as set out in SEQ ID NO:5,

(ii) CDRL2 as set out in SEQ ID NO:6, and

(iii) CDRL3 as set out in SEQ ID NO:7

2. The isolated antigen-binding protein of claim 1, which comprises a heavy chain variable region of SEQ ID NO:13.

3. The isolated antigen-binding protein of claim 1, comprising a heavy chain amino acid sequence selected from the group consisting of: SEQ ID NO:114 and SEQ ID NO:118.

4. The isolated antigen-binding protein of claim 1, comprising a heavy chain amino acid sequence selected from the group consisting of: SEQ ID NO:121 and SEQ ID NO:123.

5. The isolated antigen-binding protein of claim 1, comprising a light chain variable region of SEQ ID NO:22.

6. The isolated antigen-binding protein of claim 1, comprising a light chain of SEQ ID NO:115.

7. The isolated antigen-binding protein of claim 1, wherein said isolated antigen-binding protein comprises a heavy chain variable region as set out in SEQ ID NO:13, and a light chain variable region as set out in SEQ ID NO:22.

8. An isolated antigen-binding protein comprising the following complementarity determining regions:

(i) CDRH1 as set out in SEQ ID NO:2,

(ii) CDRH2 as set out in SEQ ID NO:3,

(iii) CDRH3 as set out in SEQ ID NO:132-137,

(iv) CDRL1 as set out in SEQ ID NO:5,

(v) CDRL2 as set out in SEQ ID NO:6, and

(vi) CDRL3 as set out in SEQ ID NO:7.

9. The isolated antigen-binding protein of claim 8, which comprises a light chain variable region of SEQ ID NO:22.

10. The isolated antigen-binding protein of claim 8, which comprises a heavy chain variable region of SEQ ID NO:13, with at least one substitution in the heavy chain, said substitution selected from the group consisting of: N98D, N98E, F100bE, F100bH, F000bI and F100bV.

11. The isolated antigen-binding protein of claim 8, which comprises a heavy chain variable region selected from the group consisting of SEQ ID NO:121, 123, 125, 127, 129 and 131.

12. An isolated nucleic acid molecule encoding an isolated antigen-binding protein according to claim 1.

13. An expression vector comprising a nucleic acid molecule according to claim 12.

14. An isolated host cell comprising an expression vector according to claim 13.

15. An isolated antigen-binding protein expressed by a host cell according to claim 14.

16 A method for the production of an isolated antigen-binding protein, comprising the step of culturing a host cell according to claim 14 in a medium to produce the isolated antigen-binding protein, and isolating or purifying the isolated antigen-binding protein therefrom.

17. A method according to claim 16, wherein said culturing step is performed in conditions conducive for expression of the isolated antigen-binding protein from the host cell, and secretion of the antibody from the cell.

18. A pharmaceutical composition comprising an isolated antigen-binding protein according to claim 1 and a pharmaceutically acceptable carrier or excipient.